+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Blood Plasma Derivatives Market - Global Forecast to 2030- Product Image
Blood Plasma Derivatives Market - Global Forecast to 2030- Product Image
Sale

Blood Plasma Derivatives Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010980
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Blood Plasma Derivatives Market grew from USD 523.83 million in 2024 to USD 576.03 million in 2025. It is expected to continue growing at a CAGR of 9.88%, reaching USD 922.24 million by 2030.

Blood plasma derivatives have emerged as a cornerstone in modern therapeutic and diagnostic applications, addressing critical needs in bleeding disorders, immunodeficiency conditions, and infectious disease management. This executive summary provides a comprehensive exploration of the market’s current state, capturing the intricate interplay of technological breakthroughs, regulatory frameworks, and evolving clinical demands. By examining the advancement of albumin products, coagulation factors, immunoglobulins, and protease inhibitors, we highlight how innovation in fractionation and recombinant technologies is expanding treatment options and improving patient outcomes. Moreover, the report delves into the increasingly strategic role of key end users, from acute inpatient clinics to specialized research institutes, underscoring the importance of tailored delivery formats such as liquid and lyophilized formulations. With a clear focus on the most impactful trends and emerging opportunities, this analysis equips decision-makers with the insights necessary to navigate a dynamic landscape. As stakeholder collaboration intensifies, from clinical practitioners to manufacturing specialists, the stage is set for continued transformation in the blood plasma derivatives arena.

Key Transformative Shifts Reshaping Blood Plasma Derivatives

Over the past decade, the blood plasma derivatives sector has undergone transformative shifts that are redefining its scope and potential. Advances in recombinant technology have catalyzed the transition from traditional human-derived albumin to recombinant albumin, reducing dependency on donor supply while enhancing safety profiles. Simultaneously, continuous improvements in chromatographic separation and fractional precipitation methods have elevated yield efficiency across all product classes, including coagulation factors such as Factor VIII, Factor IX, and prothrombin complex concentrates. The emergence of novel immunoglobulin delivery routes-particularly subcutaneous administration-has expanded patient accessibility and adherence, while innovative lyophilized formulation techniques ensure greater product stability in varied climatic conditions. On the regulatory front, harmonization efforts between major authorities are accelerating approval timelines and encouraging cross-border clinical trials, which in turn spur greater investment in next-generation therapies. Furthermore, the integration of real-world evidence and digital health platforms is enabling personalized treatment approaches, particularly for primary and secondary immunodeficiency disorders. Together, these shifts are forging a more resilient, patient-centric market landscape destined for sustainable growth.

Cumulative Impact of U.S. Tariffs on Blood Plasma Derivatives in 2025

In 2025, the implementation of revised U.S. tariffs has exerted a cumulative impact throughout the blood plasma derivatives supply chain, prompting a strategic reassessment of sourcing, manufacturing, and pricing practices. Increased duties on imported raw plasma components and finished products have elevated production costs for human serum albumin and certain coagulation factor concentrates, leading several manufacturers to diversify their procurement channels and to repatriate fractionation capacities. Consequently, domestic capacity expansion initiatives have gained momentum, with companies investing in upgraded facilities that leverage advanced fractionation techniques to offset tariff-induced expenses. In parallel, higher input costs have driven a shift toward recombinant alternatives for alpha 1-antitrypsin and albumin, as these products mitigate exposure to international trade fluctuations. Pricing pressures have also accelerated negotiations between suppliers and major hospital systems, particularly in areas serving high volumes of hemophilia A and B patients. At the same time, end users in outpatient and research settings have adapted their formulary strategies, favoring multi-dose liquid presentations that optimize inventory turnover. Altogether, the tariff landscape has galvanized the industry to innovate operationally, enhance supply chain resilience, and protect patient access.

Strategic Insights from Market Segmentation

A deep dive into market segmentation reveals nuanced opportunities and challenges across product types, applications, end users, derivation methods, patient demographics, and formulation formats. Within the primary category of type, human serum albumin and recombinant albumin are experiencing divergent growth trajectories, with the latter benefiting from lower regulatory barriers and scalable manufacturing. Coagulation factors, segmented into Factor IX, Factor VIII, and prothrombin complex concentrate, continue to dominate bleeding disorder therapies, while the rise of subcutaneous immunoglobulins alongside their intravenous counterparts is transforming care for immunodeficiency patients. Protease inhibitors, including human and recombinant alpha 1-antitrypsin, are gaining traction in pulmonary and hepatic disease management. In terms of application, therapies for hemophilia A, hemophilia B, inherited coagulopathy, and Von Willebrand disease remain foundational, yet targeted interventions for cytomegalovirus, hepatitis, and rabies are fueling infectious disease portfolios. End users spanning inpatient and outpatient clinics, general and specialty hospitals, and academic as well as private research institutes are refining procurement strategies to balance cost, availability, and patient outcomes. Method of derivation-whether chromatographic separation or fractional precipitation-influences purity and yield, while diagnostic and therapeutic uses dictate product specifications for disease diagnosis, screening procedures, therapy management, and treatment approaches. Patient age group segmentation underscores the need for tailored interventions across adult, geriatric, adolescent, and neonatal populations. Finally, the choice between liquid and lyophilized formulations affects stability, storage, and administration workflows across diverse care settings.

Distinct Regional Dynamics Driving Growth

Regional dynamics continue to shape competitive positioning and resource allocation in the blood plasma derivatives arena. In the Americas, robust domestic fractionation infrastructure and streamlined regulatory pathways facilitate rapid product roll-out for coagulation and immunoglobulin therapies, while a growing focus on recombinant albumin production drives innovation in facility automation. Europe, the Middle East, and Africa present a heterogeneous landscape, with leading markets in Western Europe emphasizing stringent quality standards and centralized procurement for rare bleeding disorders, while emerging markets in the Middle East and Africa prioritize capacity building and supply chain diversification to address infectious disease outbreaks. Asia-Pacific has witnessed significant investment in local manufacturing capabilities, particularly within China, which is expanding both liquid and lyophilized formulation lines for human alpha 1-antitrypsin and immunoglobulins. Across all regions, cross-border collaborations and public-private partnerships are enhancing clinical research infrastructure, promoting broader adoption of next-generation fractionation processes, and enabling more inclusive access to life-saving therapies.

Competitive Landscape and Leading Players

The competitive landscape in blood plasma derivatives is characterized by strategic alliances, capacity expansions, and technology acquisitions among leading players. ADMA Biologics has strengthened its immunoglobulin supply chain through targeted facility upgrades, while ARTHREX GmbH continues to integrate proprietary delivery systems to optimize therapeutic administration. Bio Products Laboratory Ltd and Biotest AG are leveraging advanced chromatographic platforms to enhance purity and yield in coagulation factor production, whereas BPL Holdings has forged partnerships to expand its recombinant albumin portfolio. China Biologic Products Holdings, Inc., and Shanghai RAAS Blood Products Co., Ltd. are elevating their global presence via investments in fractional precipitation technologies, complemented by Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.’s focus on lyophilized formulation stability. CSL Behring and Grifols maintain leadership in plasma collection networks and R&D pipelines for rare bleeding disorders. Emergent BioSolutions and Intas Pharmaceuticals are capitalizing on infectious disease therapeutics, while Kamada Ltd. and Kedrion Biopharma emphasize niche patient segments through specialized alpha 1-antitrypsin and coagulation factor concentrates. LFB Group and Octapharma continue to diversify application portfolios, and Prothya Biosolutions, RAAS Blood Products, Sanquin, and Takeda Pharmaceutical Company Limited drive market expansion via scalable manufacturing platforms and robust licensing agreements.

Actionable Recommendations for Industry Leaders

To maintain a competitive edge and ensure sustainable market leadership, industry stakeholders should prioritize several strategic actions. First, investment in advanced fractionation techniques and modular manufacturing units will reduce dependency on imported raw materials and mitigate the impact of trade barriers. Secondly, accelerating the development and adoption of recombinant alternatives for key proteins can enhance supply stability and streamline regulatory approvals. Third, establishing integrated digital platforms that capture real-world evidence will support personalized treatment protocols and facilitate value-based pricing models with payers. Fourth, collaboration with clinical networks and research institutes should expand patient registries for rare coagulopathies, thereby generating data to support novel indications and label expansions. Fifth, optimizing formulation portfolios-balancing liquid presentations for acute settings with lyophilized products for remote or resource-limited regions-will improve inventory management and broaden market reach. Finally, forging strategic alliances across regions and with contract development and manufacturing organizations will accelerate capacity scale-up while sharing commercial risk.

Conclusion and Outlook

The blood plasma derivatives market stands at a pivotal juncture, shaped by technological innovation, evolving regulatory landscapes, and shifting global trade policies. This analysis underscores the critical importance of operational agility, diversified sourcing strategies, and collaborative partnerships to navigate emerging challenges and capitalize on growth opportunities. By integrating advanced derivation methods, expanding regional footprints, and leveraging real-world data, stakeholders can deliver enhanced patient outcomes while driving sustained commercial success. As the industry moves forward, a balanced approach that aligns scientific innovation with pragmatic market execution will define the next chapter in life-saving therapies.

Market Segmentation & Coverage

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Albumin
    • Human Serum Albumin
    • Recombinant Albumin
  • Coagulation Factors
    • Factor IX
    • Factor VIII
    • Prothrombin Complex Concentrate
  • Immunoglobulins
    • Intravenous Immunoglobulins
    • Subcutaneous Immunoglobulins
  • Protease Inhibitors
    • Human Alpha 1-Antitrypsin
    • Recombinant Alpha 1-Antitrypsin
  • Bleeding Disorders
    • Hemophilia A
    • Hemophilia B
    • Inherited Coagulopathy
    • Von Willebrand Disease
  • Immunodeficiency Disorders
    • Primary Immunodeficiency Disorders
    • Secondary Immunodeficiency Disorders
  • Infectious Diseases
    • Cytomegalovirus
    • Hepatitis
    • Rabies
  • Clinics
    • Inpatient Clinics
    • Outpatient Clinics
  • Hospitals
    • General Hospitals
    • Specialty Hospitals
  • Research Institutes
    • Academic Research Institutes
    • Private Research Institutes
  • Diagnostic Use
    • Disease Diagnosis
    • Screening Procedures
  • Therapeutic Use
    • Therapy Management
    • Treatment Approaches
  • Adult
  • Geriatric
  • Pediatric
    • Adolescent
    • Neonatal
  • Chromatographic Separation
  • Fractional Precipitation
  • Liquid
  • Lyophilized

This research report categorizes the Blood Plasma Derivatives Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Blood Plasma Derivatives Market to delves into recent significant developments and analyze trends in each of the following companies:

  • ADMA Biologics
  • ARTHREX GmbH
  • Bio Products Laboratory Ltd
  • Biotest AG
  • BPL Holdings
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Intas Pharmaceuticals
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB Group
  • Octapharma
  • Prothya Biosolutions
  • RAAS Blood Products
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Blood Plasma Derivatives Market, by Type
8.1. Introduction
8.2. Albumin
8.2.1. Human Serum Albumin
8.2.2. Recombinant Albumin
8.3. Coagulation Factors
8.3.1. Factor IX
8.3.2. Factor VIII
8.3.3. Prothrombin Complex Concentrate
8.4. Immunoglobulins
8.4.1. Intravenous Immunoglobulins
8.4.2. Subcutaneous Immunoglobulins
8.5. Protease Inhibitors
8.5.1. Human Alpha 1-Antitrypsin
8.5.2. Recombinant Alpha 1-Antitrypsin
9. Blood Plasma Derivatives Market, by Application
9.1. Introduction
9.2. Bleeding Disorders
9.2.1. Hemophilia A
9.2.2. Hemophilia B
9.2.3. Inherited Coagulopathy
9.2.4. Von Willebrand Disease
9.3. Immunodeficiency Disorders
9.3.1. Primary Immunodeficiency Disorders
9.3.2. Secondary Immunodeficiency Disorders
9.4. Infectious Diseases
9.4.1. Cytomegalovirus
9.4.2. Hepatitis
9.4.3. Rabies
10. Blood Plasma Derivatives Market, by End User
10.1. Introduction
10.2. Clinics
10.2.1. Inpatient Clinics
10.2.2. Outpatient Clinics
10.3. Hospitals
10.3.1. General Hospitals
10.3.2. Specialty Hospitals
10.4. Research Institutes
10.4.1. Academic Research Institutes
10.4.2. Private Research Institutes
11. Blood Plasma Derivatives Market, by Function
11.1. Introduction
11.2. Diagnostic Use
11.2.1. Disease Diagnosis
11.2.2. Screening Procedures
11.3. Therapeutic Use
11.3.1. Therapy Management
11.3.2. Treatment Approaches
12. Blood Plasma Derivatives Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
12.4. Pediatric
12.4.1. Adolescent
12.4.2. Neonatal
13. Blood Plasma Derivatives Market, by Method Of Derivation
13.1. Introduction
13.2. Chromatographic Separation
13.3. Fractional Precipitation
14. Blood Plasma Derivatives Market, by Formulation
14.1. Introduction
14.2. Liquid
14.3. Lyophilized
15. Americas Blood Plasma Derivatives Market
15.1. Introduction
15.2. Argentina
15.3. Brazil
15.4. Canada
15.5. Mexico
15.6. United States
16. Asia-Pacific Blood Plasma Derivatives Market
16.1. Introduction
16.2. Australia
16.3. China
16.4. India
16.5. Indonesia
16.6. Japan
16.7. Malaysia
16.8. Philippines
16.9. Singapore
16.10. South Korea
16.11. Taiwan
16.12. Thailand
16.13. Vietnam
17. Europe, Middle East & Africa Blood Plasma Derivatives Market
17.1. Introduction
17.2. Denmark
17.3. Egypt
17.4. Finland
17.5. France
17.6. Germany
17.7. Israel
17.8. Italy
17.9. Netherlands
17.10. Nigeria
17.11. Norway
17.12. Poland
17.13. Qatar
17.14. Russia
17.15. Saudi Arabia
17.16. South Africa
17.17. Spain
17.18. Sweden
17.19. Switzerland
17.20. Turkey
17.21. United Arab Emirates
17.22. United Kingdom
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. ADMA Biologics
18.3.2. ARTHREX GmbH
18.3.3. Bio Products Laboratory Ltd
18.3.4. Biotest AG
18.3.5. BPL Holdings
18.3.6. China Biologic Products Holdings, Inc.
18.3.7. CSL Behring
18.3.8. Emergent BioSolutions
18.3.9. Grifols
18.3.10. Intas Pharmaceuticals
18.3.11. Kamada Ltd.
18.3.12. Kedrion Biopharma
18.3.13. LFB Group
18.3.14. Octapharma
18.3.15. Prothya Biosolutions
18.3.16. RAAS Blood Products
18.3.17. Sanquin
18.3.18. Shanghai RAAS Blood Products Co., Ltd.
18.3.19. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
18.3.20. Takeda Pharmaceutical Company Limited
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. BLOOD PLASMA DERIVATIVES MARKET MULTI-CURRENCY
FIGURE 2. BLOOD PLASMA DERIVATIVES MARKET MULTI-LANGUAGE
FIGURE 3. BLOOD PLASMA DERIVATIVES MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BLOOD PLASMA DERIVATIVES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HUMAN SERUM ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT ALBUMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTHROMBIN COMPLEX CONCENTRATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HUMAN ALPHA 1-ANTITRYPSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT ALPHA 1-ANTITRYPSIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA A, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA B, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INHERITED COAGULOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY VON WILLEBRAND DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SECONDARY IMMUNODEFICIENCY DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CYTOMEGALOVIRUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GENERAL HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SPECIALTY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIVATE RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SCREENING PROCEDURES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPY MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TREATMENT APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEONATAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CHROMATOGRAPHIC SEPARATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FRACTIONAL PRECIPITATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY LYOPHILIZED, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 136. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 137. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 138. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 139. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 140. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 141. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 142. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 143. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 144. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 145. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 147. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 148. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 149. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 150. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 151. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 152. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 154. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 155. CANADA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 156. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 157. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 158. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 159. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 160. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 161. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 162. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 163. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 164. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 165. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 167. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 169. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 170. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 171. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 173. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 174. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 175. MEXICO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 176. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 177. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 178. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 179. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 180. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 181. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 197. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 198. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 199. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 200. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 201. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 202. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 203. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 218. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 219. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 220. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 221. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 222. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 223. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 224. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 225. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 238. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 239. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 240. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 241. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 242. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 243. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 244. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 245. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 246. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 247. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 248. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 249. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 250. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 251. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 252. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 253. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 254. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 255. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 256. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 257. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 258. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 259. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 260. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 261. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 262. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 263. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 265. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 266. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 267. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 268. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 269. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 270. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 271. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 272. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 273. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 274. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 275. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 276. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 277. INDIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 281. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 282. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 283. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 284. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 285. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 286. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 287. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 288. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 291. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 294. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 296. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 297. INDONESIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 298. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 300. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 301. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 302. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 303. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 304. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY BLEEDING DISORDERS, 2018-2030 (USD MILLION)
TABLE 305. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNODEFICIENCY DISORDERS, 2018-2030 (USD MILLION)
TABLE 306. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 307. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 308. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 309. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 310. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 311. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 312. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DIAGNOSTIC USE, 2018-2030 (USD MILLION)
TABLE 313. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY THERAPEUTIC USE, 2018-2030 (USD MILLION)
TABLE 314. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 315. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PEDIATRIC, 2018-2030 (USD MILLION)
TABLE 316. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY METHOD OF DERIVATION, 2018-2030 (USD MILLION)
TABLE 317. JAPAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
TABLE 318. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 319. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, 2018-2030 (USD MILLION)
TABLE 320. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTORS, 2018-2030 (USD MILLION)
TABLE 321. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULINS, 2018-2030 (USD MILLION)
TABLE 322. MALAYSIA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2030 (USD MILLION)
TABLE 323. MALAYSIA BLOOD PLASMA DE

Companies Mentioned

  • ADMA Biologics
  • ARTHREX GmbH
  • Bio Products Laboratory Ltd
  • Biotest AG
  • BPL Holdings
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Grifols
  • Intas Pharmaceuticals
  • Kamada Ltd.
  • Kedrion Biopharma
  • LFB Group
  • Octapharma
  • Prothya Biosolutions
  • RAAS Blood Products
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Blood Plasma Derivatives Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033 - Product Image

Blood Plasma Derivatives Market Size, Share, Trends and Forecast by Type, Application, End User, and Region, 2025-2033

  • Report
  • 149 Pages
  • Global
From
Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033 - Product Image

Blood Plasma Derivatives Global Market Opportunities and Strategies to 2033

  • Report
  • 327 Pages
  • Global
From
Bovine Blood Plasma Derivatives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Bovine Blood Plasma Derivatives - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Blood Plasma Derivatives Market Report 2025 - Product Image

Blood Plasma Derivatives Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Blood Plasma Derivatives Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Blood Plasma Derivatives Global Market Insights 2025, Analysis and Forecast to 2030, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 93 Pages
  • Global
From

About the Plasma Derivative Market

The Plasma Derivative market is a subset of the Blood Banking industry, which involves the collection, processing, and distribution of human blood and its components. Plasma derivatives are products derived from human plasma, such as albumin, immunoglobulins, and clotting factors. These products are used to treat a variety of medical conditions, including hemophilia, immune deficiencies, and shock. Plasma derivatives are typically collected from healthy donors and processed in a laboratory setting. The process involves separating the plasma from the other components of the blood, such as red and white blood cells. The plasma is then further processed to create the desired product. The Plasma Derivative market is highly regulated, with stringent safety and quality standards in place to ensure the safety of the products. Companies in the market include CSL Behring, Grifols, Octapharma, Kedrion, and Biotest. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.